Changes in Hong Kong stocks | Insi+Silicon Intelligence (03696) rose more than 8% in early trading, with revenue exceeding US$100 million in the first half of the year to verify the viability of commercializing “AI+Biotech”

The Zhitong Finance App learned that Insili Intelligence (03696) rose more than 8% in early trading. As of press release, it had risen 8.03% to HK$43.04, with a turnover of HK$411 million.

According to the news, Insili Intelligence recently issued a profit announcement for the first half of the year. The estimated revenue for the period is about US$102.5 million to US$106.5 million, an increase of about 272.7% to 287.3% over the previous year; net profit is about US$33.5 million to US$39.5 million, and the adjusted net profit is expected to be around US$45.5 million to US$51.5 million. This performance mainly benefits from the Group's strategic initiatives to continuously promote revenue growth, as well as systematic improvements in operational efficiency.

According to incomplete statistics, the total amount of major new transactions signed by Insilicon Smart in 2026 exceeds 7 billion US dollars. Of these, it has disclosed that it is entitled to receive more than 175 million US dollars in down payments and milestone payments in the near future. This figure has reached more than three times the revenue of 2025. Its AI pharmaceutical platform Pharma.ai shortened the early development cycle from 4.5 years to 18 months, and 13 projects entered clinical trials. In terms of pipelines, the world's first AI-generated drug, Rentosertib Sprint Phase III. The $7 billion BD partnership and platform ecosystem built a dual engine to verify the commercial viability of “AI+Biotech”.